Literature DB >> 25028783

Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis.

Julius Chapiro1, Laura D Wood, MingDe Lin, Rafael Duran, Toby Cornish, David Lesage, Vivek Charu, Rüdiger Schernthaner, Zhijun Wang, Vania Tacher, Lynn Jeanette Savic, Ihab R Kamel, Jean-François Geschwind.   

Abstract

PURPOSE: To evaluate the diagnostic performance of three-dimensional ( 3D three-dimensional ) quantitative enhancement-based and diffusion-weighted volumetric magnetic resonance (MR) imaging assessment of hepatocellular carcinoma ( HCC hepatocellular carcinoma ) lesions in determining the extent of pathologic tumor necrosis after transarterial chemoembolization ( TACE transarterial chemoembolization ).
MATERIALS AND METHODS: This institutional review board-approved retrospective study included 17 patients with HCC hepatocellular carcinoma who underwent TACE transarterial chemoembolization before surgery. Semiautomatic 3D three-dimensional volumetric segmentation of target lesions was performed at the last MR examination before orthotopic liver transplantation or surgical resection. The amount of necrotic tumor tissue on contrast material-enhanced arterial phase MR images and the amount of diffusion-restricted tumor tissue on apparent diffusion coefficient ( ADC apparent diffusion coefficient ) maps were expressed as a percentage of the total tumor volume. Visual assessment of the extent of tumor necrosis and tumor response according to European Association for the Study of the Liver ( EASL European Association for the Study of the Liver ) criteria was performed. Pathologic tumor necrosis was quantified by using slide-by-slide segmentation. Correlation analysis was performed to evaluate the predictive values of the radiologic techniques.
RESULTS: At histopathologic examination, the mean percentage of tumor necrosis was 70% (range, 10%-100%). Both 3D three-dimensional quantitative techniques demonstrated a strong correlation with tumor necrosis at pathologic examination (R(2) = 0.9657 and R(2) = 0.9662 for quantitative EASL European Association for the Study of the Liver and quantitative ADC apparent diffusion coefficient , respectively) and a strong intermethod agreement (R(2) = 0.9585). Both methods showed a significantly lower discrepancy with pathologically measured necrosis (residual standard error [ RSE residual standard error ] = 6.38 and 6.33 for quantitative EASL European Association for the Study of the Liver and quantitative ADC apparent diffusion coefficient , respectively), when compared with non- 3D three-dimensional techniques ( RSE residual standard error = 12.18 for visual assessment).
CONCLUSION: This radiologic-pathologic correlation study demonstrates the diagnostic accuracy of 3D three-dimensional quantitative MR imaging techniques in identifying pathologically measured tumor necrosis in HCC hepatocellular carcinoma lesions treated with TACE transarterial chemoembolization . © RSNA, 2014 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25028783      PMCID: PMC4263418          DOI: 10.1148/radiol.14140033

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  35 in total

Review 1.  The use of "overall accuracy" to evaluate the validity of screening or diagnostic tests.

Authors:  Anthony J Alberg; Ji Wan Park; Brant W Hager; Malcolm V Brock; Marie Diener-West
Journal:  J Gen Intern Med       Date:  2004-05       Impact factor: 5.128

Review 2.  Gestalt theory: implications for radiology education.

Authors:  Nicholas A Koontz; Richard B Gunderman
Journal:  AJR Am J Roentgenol       Date:  2008-05       Impact factor: 3.959

3.  CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations.

Authors:  Srinivasa R Prasad; Kartik S Jhaveri; Sanjay Saini; Peter F Hahn; Elkan F Halpern; James E Sumner
Journal:  Radiology       Date:  2002-11       Impact factor: 11.105

4.  Treatment response classification of liver metastatic disease evaluated on imaging. Are RECIST unidimensional measurements accurate?

Authors:  Michael Mantatzis; Stylianos Kakolyris; Kyriakos Amarantidis; Anastasios Karayiannakis; Panos Prassopoulos
Journal:  Eur Radiol       Date:  2009-02-24       Impact factor: 5.315

5.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

6.  Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma.

Authors:  Jordi Rimola; Alejandro Forner; Maria Reig; Ramon Vilana; Carlos Rodríguez de Lope; Carmen Ayuso; Jordi Bruix
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

Review 7.  Design and endpoints of clinical trials in hepatocellular carcinoma.

Authors:  Josep M Llovet; Adrian M Di Bisceglie; Jordi Bruix; Barnett S Kramer; Riccardo Lencioni; Andrew X Zhu; Morris Sherman; Myron Schwartz; Michael Lotze; Jayant Talwalkar; Gregory J Gores
Journal:  J Natl Cancer Inst       Date:  2008-05-13       Impact factor: 13.506

8.  Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres.

Authors:  Ahsun Riaz; Laura Kulik; Robert J Lewandowski; Robert K Ryu; Georgia Giakoumis Spear; Mary F Mulcahy; Michael Abecassis; Talia Baker; Vanessa Gates; Ritu Nayar; Frank H Miller; Kent T Sato; Reed A Omary; Riad Salem
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

9.  Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients.

Authors:  Bachir Taouli; Valérie Vilgrain; Erik Dumont; Jean-Luc Daire; Bo Fan; Yves Menu
Journal:  Radiology       Date:  2003-01       Impact factor: 11.105

Review 10.  Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet
Journal:  Radiology       Date:  2003-01       Impact factor: 11.105

View more
  50 in total

1.  Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?

Authors:  Yan Zhao; Rafael Duran; Wei Bai; Sonia Sahu; Wenjun Wang; Sven Kabus; MingDe Lin; Guohong Han; Jean-François Geschwind
Journal:  Cardiovasc Intervent Radiol       Date:  2017-10-30       Impact factor: 2.740

2.  Efficacy of radiofrequency ablation of hepatocellular carcinoma prior to liver transplantation and the need for competing-risk analysis.

Authors:  Alessandro Cucchetti; Matteo Serenari
Journal:  Hepatobiliary Surg Nutr       Date:  2018-08       Impact factor: 7.293

Review 3.  Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions.

Authors:  R Duran; J Chapiro; R E Schernthaner; J-F H Geschwind
Journal:  Br J Radiol       Date:  2015-05-15       Impact factor: 3.039

4.  Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver.

Authors:  Julius Chapiro; Rafael Duran; MingDe Lin; Rüdiger Schernthaner; David Lesage; Zhijun Wang; Lynn Jeanette Savic; Jean-François Geschwind
Journal:  Eur Radiol       Date:  2015-01-31       Impact factor: 5.315

5.  The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma.

Authors:  Susanne Smolka; Julius Chapiro; Wilfred Manzano; John Treilhard; Eric Reiner; Yanhong Deng; Yan Zhao; Bernd Hamm; James S Duncan; Bernhard Gebauer; MingDe Lin; Jean-François Geschwind
Journal:  Clin Imaging       Date:  2017-06-07       Impact factor: 1.605

6.  Radiologic-pathologic analysis of quantitative 3D tumour enhancement on contrast-enhanced MR imaging: a study of ROI placement.

Authors:  Arun Chockalingam; Rafael Duran; Jae Ho Sohn; Rüdiger Schernthaner; Julius Chapiro; Howard Lee; Sonia Sahu; Sonny Nguyen; Jean-François Geschwind; MingDe Lin
Journal:  Eur Radiol       Date:  2015-05-21       Impact factor: 5.315

7.  Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies.

Authors:  Lynn J Savic; Julius Chapiro; Eliot Funai; Khaled Bousabarah; Isabel T Schobert; Edvin Isufi; Jean-Francois H Geschwind; Sophie Stark; Ping He; Michelle A Rudek; Juan Carlos Perez Lozada; Rajasekhara Ayyagari; Jeffrey Pollak; Todd Schlachter
Journal:  Eur Radiol       Date:  2020-10-15       Impact factor: 5.315

Review 8.  Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation.

Authors:  Lin Mu; Julius Chapiro; Jeremiah Stringam; Jean-François Geschwind
Journal:  Cancer J       Date:  2016 Nov/Dec       Impact factor: 3.360

9.  Non-measurable infiltrative HCC: is post-contrast attenuation on CT a sign of tumor response?

Authors:  Hasmik Koulakian; Wassim Allaham; Valérie Vilgrain; Maxime Ronot
Journal:  Eur Radiol       Date:  2018-11-09       Impact factor: 5.315

10.  Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer.

Authors:  Rafael Duran; Sahar Mirpour; Vasily Pekurovsky; Shanmugasundaram Ganapathy-Kanniappan; Cory F Brayton; Toby C Cornish; Boris Gorodetski; Juvenal Reyes; Julius Chapiro; Rüdiger E Schernthaner; Constantine Frangakis; MingDe Lin; Jessica D Sun; Charles P Hart; Jean-François Geschwind
Journal:  Clin Cancer Res       Date:  2016-07-20       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.